Company: RGNT
Filing Date: 2025-05-19
Form Type: F-1/A
Source: 0001213900-25-045479
Chunk: 278

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-05-19
Form: F-1/A
Chunk 278
---

preferred A share then held; plus (ii) a rate of return equal to 8% annually compounded thereupon, calculated from the applicable original
issue date of each such convertible preferred A shares, less any dividends actually paid on such convertible preferred A share.

Upon completion of the distribution
as described above, if any of the Company’s assets and funds legally available for distribution remain in the Company, all shareholders
of the Company (ordinary and preferred) will participate in the distribution of such remaining assets and funds of the Company, on a
pro-rata basis according to their respective holdings in the Company, calculated on an as-converted basis.

<div align='center'>F-25</div>

REGENTIS BIOMATERIALS LTD.

NOTES TO FINANCIAL STATEMENTS

U.S. dollars in thousands, except share and per share data

| NOTE 10:- | TEMPORARY EQUITY (Cont.) |

Notwithstanding the foregoing, if
the aggregate distribution pursuant to the above, together with their pro rata participation, would not result in the holders of convertible
preferred D shares receiving an amount per share of at 2 times the applicable original issue price for each convertible preferred D share,
then each holder of convertible preferred D shares will be entitled to receive in respect of each share held by such holder of convertible
preferred D share, interest at a rate of 15% per annum of the applicable original issue price of such convertible preferred D share,
compounded annually from the date of the actual payment thereto to the date of distribution, until such time that each holder of convertible
preferred D shares receives an aggregate amount of 2 times the respective original issue price for each convertible preferred D share.

In the event of a “Deemed Liquidation”,
which is a sale of all or substantially all of the assets of the Company (including, the grant of an exclusive license to all or substantially
all of the intellectual property rights of the Company), in a single transaction or a series of related transactions, the Company and
its shareholders will take such actions as are required to effect a distribution in accordance with Company’s AOA, unless each
of the holders of convertible preferred shares vote collectively against effecting such distribution.

In the event of an IPO, the conversion
price of the preferred shares shall be adjusted to reflect a deemed liquidation distribution to the preferred shares as provided in the
AOA, such that the number of Ordinary Shares issuable upon conversion thereof reflects that number of Ordinary Shares that would have